二甲双胍治疗与成人ITP合并T2DM患者结局的关联
该回顾性队列研究纳入458例ITP患者,其中合并T2DM者35例(7.6%)。合并T2DM患者治疗反应率显著高于无T2DM者(71% vs 53%),在T2DM队列中加用二甲双胍者反应率达88%。作者认为二甲双胍治疗可能改善ITP临床结局。
要点
- 458例ITP患者中合并T2DM者35例,患病率7.6%,略低于中国全国T2DM患病率约10.9%。
- 合并T2DM的ITP患者治疗反应率71%,显著高于无T2DM者的53%。
- T2DM队列中治疗方案含二甲双胍者反应率达88%。
核心结论
- 该临床证据提示二甲双胍治疗可能改善ITP的临床结局。
研究设计与样本
- 回顾性队列研究,纳入458例ITP患者。
主要发现
- 该人群T2DM患病率为7.6%(35例患者),略低于中国全国T2DM患病率约10.9%。
- 合并T2DM的ITP患者治疗反应率71%,显著高于无T2DM者的53%。
- T2DM队列中治疗方案含二甲双胍者反应率达88%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary immune thrombocytopenia (ITP) is an autoimmune haemorrhagic disease that could manifest with comorbid type 2 diabetes mellitus (T2DM). However, the exact impact of T2DM in patients with ITP remains uncertain. In this study, we performed a retrospective cohort study of 458 participants with ITP. The prevalence of T2DM was 7.6% in this population (35 patients), which was slightly lower than the Chinese nationwide prevalence of T2DM, calculated to be approximately 10.9%. The participants with pre-existing T2DM displayed a significantly higher response to therapy than those without T2DM (71% vs. 53%). Furthermore, in the T2DM cohort, the response rate reached 88% when metformin was included in the treatment regimen. This clinical evidence suggests that metformin therapy might improve the clinical outcomes of ITP.
引用
- Li C, Sun M, Li R, et al. Association of metformin treatment and outcome in adult patients with ITP and pre-existing T2DM. Br J Haematol. 2022. PMID: 35288929. doi:10.1111/bjh.18121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。